Parabilis Medicines, Inc. has 3 Schedule 13D or 13G filings on record since 2026-06-18. 3 holders' latest filing reports 5% or more of common stock, $0.0001 par value. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| RA Capital Management, L.P. | 23.8% | 28,933,371 | SCHEDULE 13D, 2026-06-18 | 2026-06-11 |
| Fmr LLC | 8.5% | 10,292,735 | SCHEDULE 13G, 2026-08-06 | 2026-06-30 |
| ARCH Venture Fund XII, L.P. | 5.3% | 6,412,780 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
Purpose of Transaction (Item 4)
RA Capital Management, L.P.
The Reporting Persons acquired the voting common stock reported herein for investment purposes and not with an intent, purpose or effect of changing control of the Issuer. The Reporting Persons may, from time to time, acquire additional equity securities or debt securities of the Issuer, which debt securities may be convertible or non-convertible, secured or unsecured, and could involve the monetization of potential revenue streams deriving from development-stage or commercial programs of the Issuer, or dispose of Issuer securities they beneficially own, on the open market or in private transactions or otherwise (including by means of 10b5-1 programs), consistent with their investment purposes and in amounts, on such terms and at such times as to be determined by the Reporting Persons based upon a number of factors, including, without limitation, their ongoing assessment of the Issuer's business prospects, the availability of Issuer securities at prices that would make the purchase or sale of such securities desirable, prevailing market conditions, the availability of other investment opportunities, and/or other considerations. In addition, consistent with their investment purpose, the Reporting Persons may engage in communications with persons associated with the Issuer, including stockholders of the Issuer, officers of the Issuer, members of the board of directors of the Issuer, and/or or other third parties, to discuss matters regarding the Issuer, including but not …The first part of Item 4 of the SCHEDULE 13D filed 2026-06-18; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-06-18 | RA Capital Management, L.P. | 23.8% | SCHEDULE 13D |
| 2026-08-06 | Fmr LLC | 8.5% | SCHEDULE 13G |
| 2026-08-14 | ARCH Venture Fund XII, L.P. | 5.3% | SCHEDULE 13G |
Tools for this story
Each opens in a new tab, filled in for Parabilis Medicines, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.